REG - CelLBxHealth PLC - Collaboration with AdventHealth for two studies

CellbxhealthAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260518:nRSR6892Ea&default-theme=true

RNS Number : 6892E  CelLBxHealth PLC  18 May 2026

 

CelLBxHealth plc

 ("CelLBxHealth" or "the Company")

 

Collaboration with AdventHealth for two studies monitoring CTCs to improve
cancer care

 

·    AdventHealth, one of the largest faith-based health systems in the
United States

·    CTC analysis will be an endpoint in two multi-centre studies in
colon, gastrointestinal and lung cancer

 

Guildford, UK and Plymouth Meeting, U.S. - 18 May 2026 - CelLBxHealth plc
(AIM:CLBX), a CTC intelligence company specialising in innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology, announces a collaboration with AdventHealth, one of the largest
faith-based health systems in the United States, for the use of CelLBxHealth's
Parsortix® platform in two  clinical studies. The studies, titled ACTION and
SUNRISE, will employ minimally invasive cancer monitoring by isolating and
analysing circulating tumour cells (CTCs) from patients undergoing treatment.

 

These studies mark an important advance in the use of minimally invasive
diagnostics to better understand treatment response, improve outcomes, and
expand access to precision oncology in community settings. Using the Parsortix
platform, researchers will isolate and analyse CTCs from blood samples,
enabling both enumeration and PD-L1 characterisation to provide real-time
insight into tumour biology without the need for invasive biopsies.

 

The ACTION study (Adaptive Randomization of Aerobic Exercise During
Chemotherapy in Colon Cancer) is a multi-site, NIH-funded trial currently
enrolling 219 patients to evaluate how different doses of aerobic exercise
influence chemotherapy tolerability in colon cancer patients (NCT05773144).
The SUNRISE study (Statewide Unified Network for Remote Intervention of
Strength and Exercise) is a digitally enabled trial in 120 patients with
gastrointestinal and lung cancers, assessing whether remotely delivered
exercise interventions can improve chemotherapy tolerance and quality of life
expected to commence in July 2026. Across both studies, CTC analysis will
serve as a novel correlative endpoint, helping researchers understand how the
tumour evolves in response to treatment and behavioural interventions.

 

A central aim of both studies is to enable more patient-centric care by
bringing advanced cancer monitoring closer to patients' homes. With most
cancer patients in the United States treated in the community, the combination
of remote interventions and simple blood-based diagnostics has the potential
to reduce patient burden, minimise travel, and support continuous monitoring
regardless of location. This approach also addresses persistent health
inequalities that limit access to specialised cancer care, particularly for
underserved populations.

 

AdventHealth's extensive national network of hospitals and outpatient
facilities provides a powerful platform to scale these innovations in
real-world clinical practice. For CelLBxHealth, the collaboration represents a
significant commercial opportunity to validate and expand adoption of the
Parsortix platform across a large, integrated healthcare system, supporting
broader use of liquid biopsy in routine oncology care.

 

Peter Collins, CEO of CelLBxHealth, commented: "This collaboration with
AdventHealth demonstrates the growing importance of accessible, non-invasive
technologies in modern oncology. By enabling detailed analysis of CTCs through
a simple blood draw, we are helping to bring precision medicine into the
community and closer to patients who need it most."

 

Justin Brown, PhD, Principal Investigator and Director of the Exercise and
Cancer Biology Research Program at AdventHealth, added: "These studies allow
us to pair advanced technology with a whole-person approach to cancer care. By
combining exercise interventions with advanced biomarkers like CTCs, we aim to
improve treatment tolerance, better understand how tumours respond to therapy
and provide care that is more accessible for patients across diverse
communities."

 

As the ACTION and SUNRISE studies progress, CelLBxHealth and AdventHealth aim
to further establish the clinical utility of CTC analysis in guiding treatment
decisions and improving cancer care delivery. Together, the organisations are
working to redefine how cancer is monitored and treated, advancing a more
equitable and patient-centred model of care.

 

For further information:

 

 CelLBxHealth plc                                investor@cellbxhealth.com

 Peter Collins, Chief Executive Officer          via Walbrook PR

 Jan Groen, Executive Chairman

 Cavendish (NOMAD and Broker)

 Geoff Nash / Isaac Hooper (Corporate Finance)   +44 (0) 20 7220 0500

 Sunila de Silva (Corporate Broking)

 Nigel Birks (Life Science Specialist Sales)

 Walbrook PR (Investor and Media Relations)      Tel: +44 (0)20 7933 8780 or CelLBx@walbrookpr.com

 Paul McManus / Alice Woodings                   Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

Notes for editors

 

About AdventHealth

AdventHealth is a connected network of care that helps people feel whole -
body, mind and spirit. More than 100,000 team members across a national
footprint provide whole-person care to nearly nine million people annually
through more than 2,000 care sites that include hospitals, physician
practices, ambulatory surgery centres, outpatient clinics, home health
agencies, hospice centres, the AdventHealth app and more. Our wholistic
approach to improving the health and prosperity of our communities is inspired
by our mission to extend the healing ministry of Christ.

 

About CelLBxHealth plc

CelLBxHealth plc is a CTC intelligence company specialising in innovative
circulating tumour cell (CTC) solutions for use in research, drug development
and clinical oncology. Its patent-protected Parsortix® Platform harvests CTCs
from blood and can be integrated with existing laboratory instruments for
comprehensive downstream analysis - including whole-cell imaging, proteomic
profiling and full genomic workflows.

 

Commercial focus span three revenue streams - Product Sales of the Parsortix
platform and consumables through CRO and clinical lab partnerships, Laboratory
Services including clinical trial support and assay development delivered from
a GCLP-compliant UK facility, and Lab Developed Tests (LDTs), pursued through
a combination of strategic partnerships and in-house development.

 

For more information, visit https://cellbxhealth.com/
(https://cellbxhealth.com/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESSFFFUWEMSEII



            Copyright 2019 Regulatory News Service, all rights reserved